Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (1877 HK)
Watchlist
212
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
11 Dec 2022 09:01
China Healthcare Weekly (Dec.9) - COVID Policy Update, Biotech Growth Curve, HKEX Chapter 18A Review
China further optimized COVID policy, so as to release risks in advance and recover ASAP. The growth curve of biotech is not linear. We reviewed...
Xinyao (Criss) Wang
Follow
354 Views
Share
bearish
•
3D Medicines
•
02 Dec 2022 11:06
Pre-IPO 3D Medicines (3DM HK) - Some Points Worth the Attention; Our Thoughts on Valuation
The overall quality/core competitiveness of 3D Medicines isn't high. Its pipeline is mainly based on license-in model, which is not favored by Mr....
Xinyao (Criss) Wang
Follow
447 Views
Share
bearish
•
BeiGene
•
28 Nov 2022 09:03
BeiGene (6160.HK/BGNE.US) 22Q3 - The Price of Being an “Outlier”
Sales of current commercialized products isn't enough for BeiGene to turn loss into profit. BeiGene is fundamentally different from any other China...
Xinyao (Criss) Wang
Follow
377 Views
Share
bearish
•
Wuxi Biologics
•
27 Nov 2022 09:03
China Healthcare Weekly (Nov25)-Wuxi Biologics, Valuation Logic Changed by NRDL, Biotech Model Fails
NRDL negotiation completely changes the valuation logic of innovative drug. We've some concerns about WuXi Bio's new business updates. The model...
Xinyao (Criss) Wang
Follow
391 Views
Share
bullish
•
Shanghai Fosun Pharmaceutical (Group)
•
11 Nov 2022 12:31
Shanghai/Shenzhen Southbound Connect: Weekly Moves (11 November 2022)
Inside is a recap of movements in the Shanghai/Shenzhen-HK Connect. Overall, the net inflow over the past week was ~HK$4.1bn, split (+HK$1.7bn) for...
David Blennerhassett
Follow
378 Views
Share
First
Previous
11
12
13
14
15
16
17
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x